Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $55.39, for a total transaction of $166,170.00. Following the completion of the transaction, the director now owns 7,127 shares of the company’s stock, valued at $394,764.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Ionis Pharmaceuticals, Inc. (IONS) opened at $54.36 on Friday. The company has a market cap of $6,695.28, a P/E ratio of 357.67 and a beta of 2.90. Ionis Pharmaceuticals, Inc. has a one year low of $37.26 and a one year high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/17/insider-selling-ionis-pharmaceuticals-inc-ions-director-sells-166170-00-in-stock.html.

A number of research firms have recently commented on IONS. Stifel Nicolaus raised their price objective on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the company a “hold” rating in a research report on Wednesday, August 9th. Needham & Company LLC restated a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. BMO Capital Markets raised their price objective on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Evercore ISI began coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $65.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $50.31.

Hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC raised its stake in shares of Ionis Pharmaceuticals by 62.8% during the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after acquiring an additional 800 shares in the last quarter. Aviva PLC purchased a new position in shares of Ionis Pharmaceuticals during the second quarter worth approximately $10,187,000. Allen Investment Management LLC raised its stake in shares of Ionis Pharmaceuticals by 64.7% during the second quarter. Allen Investment Management LLC now owns 15,652 shares of the company’s stock worth $796,000 after acquiring an additional 6,147 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Ionis Pharmaceuticals by 21.4% during the second quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after acquiring an additional 3,538 shares in the last quarter. Finally, Bank of Nova Scotia purchased a new position in shares of Ionis Pharmaceuticals during the second quarter worth approximately $1,526,000. 88.98% of the stock is currently owned by hedge funds and other institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.